



Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
Direct Dial: 800-772-6436
Fax: 866-292-6436

David Cohan, MD / FACS
Medical Director
United States Medical Lead talimogene laherparepvec (IMLYGIC®)
Amgen, Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
dcohan@amgen.com

October 16, 2017

NCCN Guidelines Panel: **Melanoma**

Dear Panel Members,

In follow up to our letter dated June 29, 2017, I am happy to provide you with data from two clinical trials of IMLYGIC® (talimogene laherparepvec) in combination with checkpoint inhibitors that have recently been published in two peer-reviewed scientific journals:


- Chesney et al., J Clin Oncol 35. © 2017 by American Society of Clinical Oncology
<https://doi.org/10.1200/JCO.2017.73.7379>
- Ribas et al., 2017, Cell 170, 1109–1119 September 7, 2017 © 2017 Elsevier Inc.
<http://dx.doi.org/10.1016/j.cell.2017.08.027>

IMLYGIC® (talimogene laherparepvec) is approved by the US FDA for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use: IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases.

IMLYGIC is not currently approved by the US FDA for use in combination with checkpoint inhibitors.

Enclosed are full reprints of both publications for your information. Thank you.

Sincerely,



David Cohan, MD / FACS
Medical Director
United States Medical Lead talimogene laherparepvec (IMLYGIC®)
dcohan@amgen.com

ENCLOSURES